Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production
Open Access
- 17 January 2021
- Vol. 9 (1), 59
- https://doi.org/10.3390/vaccines9010059
Abstract
The current pandemic has highlighted the ever-increasing risk of human to human spread of zoonotic pathogens. A number of medically-relevant zoonotic pathogens are negative-strand RNA viruses (NSVs). NSVs are derived from different virus families. Examples like Ebola are known for causing severe symptoms and high mortality rates. Some, like influenza, are known for their ease of person-to-person transmission and lack of pre-existing immunity, enabling rapid spread across many countries around the globe. Containment of outbreaks of NSVs can be difficult owing to their unpredictability and the absence of effective control measures, such as vaccines and antiviral therapeutics. In addition, there remains a lack of essential knowledge of the host–pathogen response that are induced by NSVs, particularly of the immune responses that provide protection. Vaccines are the most effective method for preventing infectious diseases. In fact, in the event of a pandemic, appropriate vaccine design and speed of vaccine supply is the most critical factor in protecting the population, as vaccination is the only sustainable defense. Vaccines need to be safe, efficient, and cost-effective, which is influenced by our understanding of the host–pathogen interface. Additionally, some of the major challenges of vaccines are the establishment of a long-lasting immunity offering cross protection to emerging strains. Although many NSVs are controlled through immunisations, for some, vaccine design has failed or efficacy has proven unreliable. The key behind designing a successful vaccine is understanding the host–pathogen interaction and the host immune response towards NSVs. In this paper, we review the recent research in vaccine design against NSVs and explore the immune responses induced by these viruses. The generation of a robust and integrated approach to development capability and vaccine manufacture can collaboratively support the management of outbreaking NSV disease health risks.This publication has 213 references indexed in Scilit:
- Recombinant Rabies Viruses Expressing GM-CSF or Flagellin Are Effective Vaccines for Both Intramuscular and Oral ImmunizationsPLOS ONE, 2013
- Immune Signaling by RIG-I-like ReceptorsImmunity, 2011
- A diverse range of gene products are effectors of the type I interferon antiviral responseNature, 2011
- Ebola haemorrhagic feverThe Lancet, 2011
- Replication‐Deficient Rabies Virus–Based Vaccines Are Safe and Immunogenic in Mice and Nonhuman PrimatesThe Journal of Infectious Diseases, 2009
- Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virusProceedings of the National Academy of Sciences of the United States of America, 2009
- Influenza A Virus NS1 Targets the Ubiquitin Ligase TRIM25 to Evade Recognition by the Host Viral RNA Sensor RIG-ICell Host & Microbe, 2009
- In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responsesVaccine, 2009
- Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytesVirus Research, 2004